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Nonvalvular atrial fibrillation is the most common sustained arrythmia and an 
independent risk factor for stroke. Today, 6 million Americans live with this disease. The 
current standard of care to prevent thrombus formation are anticoagulants such as 
warfarin. Left atrial appendage occlusion devices are a recently available alternative to 
long-term anticoagulation. However, it has been learned that thrombus may form on these 
devices in the early months after deployment, so short-term antithrombotic therapy is 
recommended for up to 6 months. To date, there have been no studies to determine the 
optimal antithrombotic therapy regimen post implant. The present study reviews what is 
known about antithrombotic therapy and proposes a randomized controlled trial to 
compare the potential utility of direct oral anticoagulant therapy to the presently 
recommended strategy using warfarin and dual-antiplatelet therapy. Determining the 
proper antithrombotic profile for post device-placement patients will reduce 





Atrial fibrillation (AF) is the most common cardiac arrythmia in the United 
States.1 The lifetime risk for developing AF is 1 in 4 for men and women 40 years of age 
or older who have congestive heart failure and 1 in 6 in those who don’t.2 It afflicts 10% 
of individuals 80 or older in the United States.1 The prevalence of atrial fibrillation will 
likely increase in the coming years because its prevalence increases with age and the 
majority of our population is aging. It is estimated that by 2030, one in five Americans 
will be 65 or older.3 Along with this, the average U.S. life expectancy has increased from 
68 years in 1950, to 78.6 years in 2017.4 Thus, by the year 2030, with no increase in the 
current incidence of AF, the prevalence of AF is expected to increase from 6 million to 
9.3 million.5  
AF is sub-classified into valvular and non-valvular AF forms because the threat of 
stroke is greater and the anticoagulant treatment strategy is more stringent in valvular AF. 
Non-valvular atrial fibrillation (NVAF) results from many potential physiologic and 
pathophysiologic mechanisms such as aging, hypertension, heart failure, 
cardiomyopathies, and coronary artery disease. In many people, it is idiopathic. There 
may be underlying genetic factors that predispose to its occurrence, but this knowledge is 
in its infancy. Complications of atrial fibrillation include stroke, heart failure, 
hospitalization, cognitive dysfunction, and lower exercise capacity.6 The most disabling 




Most strokes that occur as a result of NVAF are due to formation of a thrombus in 
the left atrial appendage. A portion of the thrombus may embolize to a distant vessel and 
prevent blood flow to its vascular territory, subsequently causing ischemia to the tissue 
that is perfused by the blood vessel. This process occurring in a cerebral vessel leads to 
embolic stroke that is often large and disabling. Warfarin was the first anticoagulant used 
to minimize the occurrence of left atrial thromboembolism. It has been shown to reduce 
the risk of stroke in AF patients by approximately 60%.8 However, warfarin is not a 
perfect solution to this issue due to its many interactions with food and medications and 
the blood testing that is required to monitor the international normalized ratio (INR). INR 
monitoring is required to ensure therapeutic effect and minimize the risk of bleeding due 
to excessive anticoagulation. As many as 26 drugs and foods interact with warfarin, 
leading to both potentiation and inhibition of warfarin’s pharmacological effects. 
Nafcillin, barbiturates, carbamazepine, cholestyramine, and foods high in vitamin K 
(such as spinach and other leafy greens) can reduce levels of warfarin in the blood, 
causing the INR to drop, and subsequently increase the risk of thromboembolism. The 
opposite effect is also possible with drugs such as amiodarone that can increase the levels 
of warfarin in the blood and subsequently cause the INR to increase.9 An increase in INR 
can lead to increases in bleeding. Moreover, warfarin compliance is commonly poor, with 
one in five doses being taken incorrectly even in the setting of a dedicated 
anticoagulation clinic. An increase or decrease in INR can lead to excessive bleeding or a 
thrombotic state, respectively.10  
In 2011, direct-acting oral anticoagulants (DOAC’s) became available. Drugs 
such as dabigatran, a direct thrombin inhibitor, and the direct factor Xa inhibitors 
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rivaroxaban, apixaban, and edoxaban have expanded the field of antithrombotic therapy 
for stroke and systemic embolism prevention in NVAF.11 Apixaban has been shown to be 
superior to warfarin in preventing stroke or systemic embolism, minimizing bleeding, and 
reducing mortality.12 Rivaroxaban was shown to be noninferior to warfarin for the 
prevention of stroke or systemic embolism. There was also no significant difference in 
the risk of major bleeding and intracranial and fatal bleeding occurred less frequently in 
the rivaroxaban group.13  In a review of all four DOACs, apixaban, edoxaban, 
rivaroxaban, and dabigatran, these medications were shown to have a lower incidence of 
intra-cranial bleeding (0.6%) than warfarin (1.4% per year) with a relative risk reduction 
of 57% (95% confidence interval 31-73%).14 The DOAC trials demonstrated that patients 
could safely take those agents instead of warfarin with equivalent therapeutic efficacy, no 
additional complications, reduced risk of intra-cranial bleeding, fewer drug and food 
interactions and no need for constant monitoring of INR. Although the DOAC’s, have 
potential advantages over warfarin, they still present the problem of compliance. It is 
estimated that 50% of patients taking life-long/chronic oral medications either forget to 
take their medications regularly or do not adhere to the guidelines for taking the 
medication.15 Even fairly brief suspension of DOAC therapy has been reported to result 
in thromboembolism.13 Non-adherence is likely going to continue to be an issue and a 
major reason for concern with any antithrombotic drug prescribed for life-long 
anticoagulation.16 
Given the potential limitations of oral anticoagulation therapy to reduce stroke 
risk in NVAF, and based upon observations in patients who undergo cardiac surgery, 
resection or occlusion of the left atrial appendage has been recommended as a therapy to 
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decrease the occurrence of stroke in patients with atrial fibrillation.17 In a large 
retrospective cohort study, investigators observed that concurrent surgical left atrial 
appendage occlusion in patients undergoing coronary artery bypass graft and valve 
replacement was associated with a lower risk of subsequent stroke and all-cause 
mortality.18 Complete surgical resection of the left atrial appendage may be technically 
challenging and hazardous in some patients and, therefore, is not suitable for all patients. 
For this reason, slightly less aggressive approaches to exclusion of the left atrial 
appendage through various techniques have been proposed. Unfortunately, they have 
proved to be disappointing. In the left atrial appendage occlusion study (LAAOS), 
transesophageal echocardiographic follow-up imaging demonstrated that only 45% of 
patients in whom the opening of the left atrial appendage had been sutured, and 72%  in 
whom it had been stapled achieved complete occlusion.19 Any residual flow that may 
accompany these incomplete occlusions increases the risk of patients developing a 
thrombus and subsequent embolic complications, leading investigators to search for new 
and safer alternatives. 
 Given the risk and potential limitations of surgical approaches to left atrial 
appendage exclusion, several approaches to less invasive, transcatheter left atrial 
appendage occlusion have been devised and tested. On March 13, 2015, one such device, 
the Watchman received FDA approval for use in the USA.20 Watchman is a self-
expanding nitinol frame left atrial appendage closure (LAAC) device that can be inserted 
into the left atrial appendage via a transvenous approach incorporating transseptal 
puncture to deliver the device from the right atrium to the left atrial appendage. Once in 
the left atrial appendage, the device is expanded and a polyester fabric cover prevents 
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clots from forming in the left atrial appendage. Over several months, the device then 
undergoes endothelialization in the left atrial appendage, with the hope that this will fully 
occlude the orifice of the left atrial appendage and prevent peri-device leakage.21 The 
PROTECT AF trial showed that percutaneous placement of the Watchman LAAC device 
was non-inferior to warfarin in reducing the combined outcome of stroke, systemic 
embolism, and cardiovascular death and was superior to warfarin in reducing 
cardiovascular and all-cause mortality.22 In the PREVAIL trial, WATCHMAN placement 
was noninferior to warfarin in reducing ischemic stroke and systemic embolism.23 A 
recent study in high risk AF patients with CHA2DS2-VASc (CHF history, Hypertension 
history, Age, Diabetes history, Sex, Stroke/TIA/thromboembolism history, Vascular 
disease history) score of 5 of higher demonstrated that the Watchman device appeared to 
be safe with a residual annual ischemic stroke risk of 2.8%. In such a high-risk patient 
population, the estimated annual stroke risk is about 12% in patients not receiving oral 
anticoagulation and about 4% in those on warfarin anticoagulation.24  
Statement of the Problem 
The issue with Watchman is that the device itself may serve as the nidus for 
thrombus formation until it becomes fully endothelialized, a process that may take 3 to 6 
months.25 Thus, there is a continued need for antithrombotic therapy for at least several 
months after its placement. For this reason, in the three trials mentioned above, 
PROTECT AF, PREVAIL, and the recent WATCHMAN trials in high risk patients, all 
patients were started on oral anticoagulation after implantation of the device. This 
anticoagulation mostly consisted of warfarin and was continued for 45 days. At 45 days, 
patients were switched to clopidogrel and aspirin, a regimen that was continued for six 
6 
 
months post-procedure. This antithrombotic strategy was entirely empirical, no 
randomized studies have been conducted to determine the optimal antithrombotic therapy 
after placement of WATCHMAN. Current literature does suggest that there may be a 
better alternative to the strategy that was used in the trials above.  
It was demonstrated in the RE-DUAL PCI trial that patients with atrial fibrillation 
who had undergone PCI with coronary stent placement, and thus had indication for both 
anticoagulant and antiplatelet medication, had equivalent protection from stent 
thrombosis but a lower risk of bleeding if they took dabigatran and a P2Y12 inhibitor 
compared to warfarin, a P2Y12 inhibitor, and aspirin.
26 Two further studies of 
anticoagulation in patients with AF who undergo coronary stenting reached similar 
conclusions: therapy with a DOAC and a P2Y12 inhibitor (chiefly clopidogrel) proved to 
be superior to triple therapy with warfarin, aspirin, and clopidogrel.27,28  
One small study that examined the potential use of DOAC medication instead of 
warfarin after Watchman placement in patients at the Cleveland Clinic gave promising 
results. The study monitored 37 patients who had received DOACs (either dabigatran, 
apixaban, or rivaroxaban) for any occurrence of bleeding or thromboembolic 
complications. In this study, all 37 patients completed 45 days of DOAC medication. 
There were 4 cases of bleeding: 2 minor gastrointestinal bleeds, 1 groin hematoma, and 
one arm hematoma. There were no reported device related thrombosis, stroke, or death in 
the group. Additionally, every patient on a DOAC medication demonstrated effective left 
atrial appendage occlusion on transesophageal echocardiogram at 45 days post 
implantation.29 While this study was small, retrospective and had no control group, it 
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provides observational data supporting the use of DOAC medications after Watchman 
deployment.  
These observations raise the question about what the proper antithrombotic 
therapy should be after PCI placement of the WATCHMAN device. Might therapy with 
DOAC plus clopidogrel be superior to use of warfarin, aspirin, and clopidogrel? The 
advantages of DOACs include lack of INR monitoring, less bleeding (especially 
intracranial bleeding), and possibly decreased thromboembolic events. No prospective 
trials of DOAC therapy after Watchman implant have been conducted. The present study 
will examine if a low dose DOAC and P2Y12 inhibitor regimen after Watchman 
placement is more effective at preventing bleeding and thromboembolism compared to 
the antithrombotic therapy currently being used.  
Goals and Objectives 
 This study aims to assess if there exists a more beneficial and less harmful 
antithrombotic profile for patients who undergo Watchman device implantation. 
Specifically, this study seeks to determine if substituting apixaban for warfarin and 
adding clopidogrel in the first 45 days of antithrombotic therapy will decrease the rate of 
device-related thrombus formation over 6 months of follow-up.  Antithrombotic therapy 
after 45 days will continue as described by the current standard of care. 
 The objectives of this study are to: 1) randomize a sufficient number of patients 
who meet the inclusion criteria (and do not meet the exclusion criteria) into two separate 
groups: apixaban and clopidogrel post-procedure or warfarin and aspirin post procedure; 
2) perform transesophageal echocardiograms at 45 days and 6 months post-procedure to 
evaluate for peri-device leakage and device related thrombus; and 3) determine over 6 
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months of follow-up whether patients in either group demonstrate lower rate of device-
related thrombus formation. 
Hypothesis 
 The chief hypothesis of the study is that patients who receive the Watchman 
device and direct oral anticoagulant (apixaban) and P2Y12 inhibitor (clopidogrel) therapy 
transitioning into daily aspirin therapy will experience device associated thrombosis, over 
6 months of post-implant follow-up at a rate equal to or less than those who receive 
warfarin, transitioning to clopidogrel and aspirin, the current standard of care. 
Definitions 
Watchman- The left atrial appendage occlusion device under study (and the only device 
that has to date received FDA approval for clinical use in the USA). 
“Current standard of care”- warfarin, with target INR of 2-3, plus aspirin 81 mg daily for 
45 days post-implant of Watchman, then, if there are no signs of device-related thrombus 
or peri-device leakage, clopidogrel 75 mg daily and aspirin 81 mg daily until 6 months 
have elapsed post-device implant. After this, aspirin is continued at 81 to 324 mg daily 
indefinitely.  
Apixaban dosing- 5 mg twice daily [reduced to 2.5 mg twice daily if patient has 2 of 3 of 
the following characteristics: age of 80 or older, serum creatinine > 1.5 mg/dL or weight 
< 60 kg]. 
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A thorough literature search was conducted between July 2019 and April 2020 
using PubMed and Ovid. Keywords used initially to identify relevant articles included 
combinations of “Watchman”, “Warfarin”, “Atrial Fibrillation”, “DOAC”. All clinical 
trials, controlled studies, meta-analyses and systematic reviews that were considered 
pertinent to the topic were retained for review. After this initial search, the abstract of 
each of these articles was screened for relevance. Relevant articles were completely and 
critically reviewed. Relevant source material found within the bibliography of these 
sources was also reviewed. The entire process included 22 articles critically read and 
annotated. 
Review of Empirical Studies About the Relationship Being Studied 
History of Anticoagulation 
The need for anticoagulation in AF is an undisputed fact today in medicine. The 
decreased movement of blood in the left atrium creates an environment suitable to 
forming a thrombus. In a meta-analysis analyzing six separate trials and 2900 
participants, it was found that patients who achieved a mean International Normalized 
Ratio (INR) from 2.0-2.6 on dose-adjusted warfarin had an average stroke rate of 4.5% 
per year, far less than patients who received no anticoagulation and had a stroke rate of 
12% per year.1 In this same study, patients treated with warfarin experienced a 64% (95% 
Confidence Interval, 49% to 74%) reduction in all strokes, with the reduction in disabling 
and nondisabling stroke similar. When only ischemic strokes are taken into consideration, 
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the warfarin treated patients demonstrated a 67% (Confidence interval, 54% to 77%) 
relative risk reduction.1 It is apparent that anticoagulation in AF is a necessity, but the 
authors did acknowledge that warfarin therapy posed difficulties due to the INR blood 
testing required for its safe and effective administration and its many interactions with 
food and medications that can alter the INR.2 An alteration of the INR can cause patients 
to be hypo/hypercoagulable depending on which way the INR moves, which can lead to 
complications. The hypercoagulable state and associated complications were examined in 
a 1996 study. Patients with a mean sub-therapeutic INR level (< 2.0) were found to have 
a higher risk of stroke compared to those with therapeutic INR levels (2.0-3.0) (INR = 1.7 
hazard ratio 2.0, 95% Confidence interval 1.6-2.4, INR = 1.5 hazard ratio 3.3, 95% 
Confidence interval 2.4-4.6, INR = 1.3 hazard ratio 6.0, 95% Confidence interval 4.4-
24.5).3 Even with these known complications, dose-adjusted warfarin was the standard of 
care for AF anticoagulation for the last two to three decades of the 20th century due to its 
effectiveness in reducing stroke and mortality while patients maintained a therapeutic 
INR. 
Advancement of Anticoagulation for Atrial Fibrillation 
 Due to the difficulties associated with warfarin dosing and maintenance, direct 
oral anticoagulant (DOAC) medications were created. These medications work through 
non-vitamin K antagonistic mechanisms and are collectively referred to as direct acting 
oral anticoagulants (DOACs). The four medications in this class of drugs that are 
presently available for clinical use are dabigatran, edoxaban, rivaroxaban, and apixaban. 
 The first DOAC that was studied and approved for us by the FDA in 2010 for the 
use in patients with non-valvular AF was dabigatran. This drug works through direct 
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thrombin inhibition. Contrary to warfarin, dabigatran does not need to be monitored 
through routine blood testing and has many fewer drug and food interactions. In the 
Dabigatran versus Warfarin in Patients with Atrial Fibrillation trials (RE-LY trial), 
dabigatran was investigated as being an alternative to warfarin for reducing stroke in 
patients with AF. The RE-LY trial was a randomized control trial that sought 
noninferiority for dabigatran. A total of 18,113 patients was enrolled and the median 
duration of the follow-up period was 2 years, with complete follow up achieved in over 
99% of participants. The primary outcome of stroke or systemic embolism was 1.53% per 
year in patients receiving 110 mg of dabigatran twice daily, 1.11% per year in patients 
receiving 150 mg of dabigatran twice daily, and 1.69% per year in patients receiving 
warfarin; both doses of dabigatran were statistically noninferior to warfarin therapy in 
preventing stroke or systemic embolism (p < 0.001). The 150 mg dose of dabigatran also 
achieved superiority to warfarin for this outcome with a relative risk of 0.66 (95% 
Confidence interval 0.53-0.82, p < 0.001).4 The rates of hemorrhagic strokes were also 
lower in both dabigatran groups compared to warfarin with a relative risk of 0.31 (95% 
Confidence interval 0.17-0.56, p < 0.001) for the 110 mg group and a relative risk of 0.26 
(95% Confidence interval 0.14-0.49, p < 0.001) in the 150 mg group.4 Another concern 
with anticoagulation is an increase in bleeding. In the RE-LY trial, the relative risk in the 
110 mg group was 0.80 compared to warfarin (95% Confidence interval 0.69-0.93, p = 
0.003). However, the 150 mg group did not achieve significance in reduction of major 
bleeding compared to warfarin (relative risk 0.93, 95% Confidence interval 0.81-1.07, p 
= 0.31).4 The RE-LY trial demonstrated that dabigatran was not only noninferior to 
warfarin but superior when assessing stroke, systemic embolism, and hemorrhagic stroke, 
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all while being an easier medication for patients to take and reducing the need for routine 
INR monitoring. In another trial, REDUAL PCI, the use of dabigatran and clopidgrel was 
compared to warfarin, clopidogrel, and aspirin for patients with AF that who had 
undergone percutaneous coronary intervention with coronary stents that required 
antiplatelet therapy to prevent stent thrombosis. This study achieved noninferiority for the 
high-dose dabigatran group and noninferiority and superiority for the low-dose 
dabigatran group compared to warfarin, clopidogrel, and aspirin therapy when 
considering a primary end point of first major or clinically relevant nonmajor bleeding 
events (low-dose hazard ratio 0.52, 95% Confidence interval 0.42-0.63, p < 0.001 for 
noninferiority, p < 0.001 for superiority; high dose hazard ratio 0.72, 95% Confidence 
interval 0.58-0.88, p < 0.001 for noninferiority).5 This is another trial that demonstrates 
that dabigatran is an effective alternative to warfarin for anticoagulation in AF patients.  
 In a more recent systematic search, including observational studies comparing 
dabigatran with warfarin, dabigatran was found to be comparable (noninferior) to 
warfarin in preventing ischemic stroke among patients with AF. Patients who received 
dabigatran 150 mg twice daily had a hazard ratio of 0.92 (95% Confidence interval 0.84-
1.01, p = 0.066) when compared to warfarin.6 Dabigatran, given in a dose of 150 mg 
twice daily was also found to have a significantly greater hazard of gastrointestinal 
bleeding compared to warfarin in patients over 75 years old (hazard ratio 1.23, 95% 
Confidence interval 1.01-1.50, p = 0.041) which was not observed in the RE-LY trial.6 
This is most likely due to the fact that the RE-LY trial had a mean age of 69.4 The risk of 
gastrointestinal bleeding with dabigatran is significant, in great part due to the fact that 
the drug requires an acidic gastric milieu for optimal absorption, so it is compounded 
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with tartaric acid in the capsule. Its use necessitates careful patient selection and patient-
provider shared decision making when choosing between dabigatran and warfarin. It 
should also be noted that dabigatran, even in its highest dose, demonstrated a lower risk 
of intracranial bleeding compared with warfarin (hazard ratio 0.44, 95% Confidence 
interval 0.34-0.59, p < 0.001). In summary, studies with dabigatran demonstrate that it is 
at least non inferior to warfarin in preventing left atrial thromboembolism in patients with 
AF, is associated with lower risk of intra-cranial bleeding and provides greater 
convenience and freedom from potentially harmful interactions with food, drink, and 
medications than warfarin. Its greater tendency to cause gastro-esophageal irritation and 
bleeding represents its one potentially serious drawback compared to warfarin. 
 The second DOAC that received FDA approval for clinical use, in November 
2011, is the factor Xa inhibitor rivaroxaban. Rivaroxaban was also studied against 
warfarin in the prevention of stroke and systemic embolism in patients with AF in the 
rivaroxaban versus warfarin in nonvalvular atrial fibrillation trial (ROCKET-AF trial). 
This was a double blinded randomized control trial that enrolled over 14,000 patients 
with AF. In the primary endpoint, a composite of stroke and systemic embolism, 
rivaroxaban was found to be noninferior to warfarin with a hazard ratio of 0.79 (95% 
Confidence interval 0.66-0.96, p < 0.001).7 Major and nonmajor bleeding were also 
evaluated in the trial, with rivaroxaban having a hazard ratio of 1.03 (95% Confidence 
interval 0.96-1.11, p = 0.44).7 Lastly, the study examined intracranial hemorrhage and 
gastrointestinal bleeding between rivaroxaban and warfarin. Rivaroxaban had 
significantly less rates of intracranial hemorrhage (hazard ratio 0.67 95% Confidence 
interval 0.47-0.93) when compared to warfarin. However, rivaroxaban did have 
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significantly more gastrointestinal bleeding during the study with 224 events (3.2%) 
compared to warfarin with 154 events (2.2%) (p < 0.001).7 This study demonstrated that 
rivaroxaban was clinically a more useful drug than warfarin due to the lack of monitoring 
that is needed, noninferior nature of preventing stroke and systemic embolism, and 
superior nature of preventing intracranial hemorrhage. However, the study did highlight 
the excessive gastrointestinal bleeding events seen with rivaroxaban compared to 
warfarin. Another study examined the use of rivaroxaban over warfarin in patients with 
both AF and stage IV-V chronic kidney disease. In this study, rivaroxaban was found to 
have a hazard ratio of 0.93 (95% Confidence interval 0.46-1.90, p = 0.85) compared to 
warfarin for the risk of stroke and systemic embolism. Rivaroxaban also had a hazard 
ratio of 0.91 (95% Confidence interval 0.65-1.28, p = 0.60) compared to warfarin for 
major bleeding.8 These data did not show superiority or noninferiority, but did  
demonstrate equivalence between the two drugs. Rivaroxaban, like the other DOACs, has 
many fewer drug or food interactions than warfarin and it does not require routine INR 
monitoring.  
 The third DOAC medication available on the market is apixaban, which received 
FDA approval in December 2012. Apixaban is another factor Xa inhibitor. In the 
apixaban versus warfarin in patients with atrial fibrillation trial (ARISTOTLE), it was 
found that apixaban was both noninferior and superior to warfarin for stroke and systemic 
embolism prevention (hazard ratio 0.79 95% Confidence interval 0.66-0.95, p < 0.001 for 
noninferiority and p = 0.01 for superiority).9 The apixaban group also demonstrated 
significantly lower rates per year of major bleeding compared to the warfarin group 
(hazard ratio 0.69 95% Confidence interval 0.60-0.80, p < 0.001).9 The rate of 
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hemorrhagic stroke per year was also significantly lower in the apixaban group compared 
to the warfarin group (hazard ratio 0.51, 95% Confidence interval 0.35-0.75, p < 0.001).9 
Finally, this study showed that apixaban had a lower rate of death per year compared to 
warfarin over the duration of the study (hazard ratio 0.89, 95% Confidence interval 0.80-
0.99, p = 0.047).9 All of these findings demonstrated that apixaban, compared to 
warfarin, prevented more strokes and systemic embolism, was responsible for fewer 
events of major bleeding, reduced the rate of hemorrhagic stroke, and had a lower 
mortality rate compared to warfarin. This study cemented apixaban as one of the most 
beneficial anticoagulants in treating patients with AF. 
 The fourth DOAC medication that has been compared to warfarin in the setting of 
AF is edoxaban. Edoxaban is another direct oral factor Xa inhibitor. It was approved for 
use by the FDA in January 2015. In the edoxaban versus warfarin in patient with atrial 
fibrillation trial, (ENGAGE AF-TIMI48) high dose edoxaban (60 mg daily) was found to 
be noninferior and superior to warfarin for stroke and systemic embolism prevention with 
a hazard ratio of 0.79 (95% Confidence interval 0.63-0.99, p < 0.001 for noninferiority, p 
= 0.02 for superiority). The low dose edoxaban group (30 mg daily) was found to be 
noninferior to warfarin for stroke and systemic embolism with a hazard ratio of 1.07 
(95% Confidence interval 0.87-1.31, p = 0.005 for noninferiority and p = 0.44 for 
superiority).10 The hazard ratio for major bleeding events for high dose edoxaban 
compared to warfarin was 0.80 (95% Confidence interval 0.71-0.91, p < 0.001) and low 
dose edoxaban compared to warfarin was 0.47 (95% Confidence interval 0.41-055, p < 
0.001).10 Thus, both doses proved more beneficial than warfarin for treatment of AF due 
to the reduced side effect profile and similar, if not superior, outcomes seen in the 
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ENGAGE AF-TIMI48 trial. Another trial that examined the use of edoxaban was the 
ENSURE-AF trial. This trial compared the efficacy and safety of edoxaban to a 
combination of warfarin and enoxaparin. When considering the primary outcome of the 
study, a composite of stroke, systemic embolism, and myocardial infarction, edoxaban 
was found to have fewer events when compared to warfarin-enoxaparin therapy in both 
patients who had previously received warfarin or were warfarin naïve (0.5% vs 0.9% in 
non-naïve [odds ratio 2.09, 95% Confidence interval 0.72-6.81] and 0.3% vs 1.4% in 
naïve patients [odds ratio 0.77, 95% Confidence interval 0.15-3.60]).11 This study 
demonstrated no difference between the edoxaban and warfarin-enoxaparin patient 
groups. There was, however, one potential clinical problem with the use of edoxaban – its 
effectiveness was found to be uniquely sensitive to renal function. A 2016 study showed 
that in patients with very normal estimated creatine clearance (> 95mL/min) even high 
dose edoxaban (60 mg daily) was less effective than warfarin for prevention of stroke and 
systemic embolism.12 At estimated creatinine clearance < 30 mL/min, the dose should be 
decreased and at estimated creatinine clearance < 15 mL/min, the drug is contraindicated 
due to anticipated poor clearance. The need for such careful dose adjustment in relation 
to renal function diminishes the potential population of patients to which this drug may 
be safely prescribed.   
Selecting a DOAC 
The literature provides little guidance by which to select one DOAC over another 
for few studies have provided head-to-head comparisons of the four available agents. 
However, some analyses have emerged. In a 2020 retrospective cohort study of over 
99,000 patients who either took apixaban or rivaroxaban from December 2012 to January 
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2019, patients taking apixaban experienced ischemic stroke or systemic embolism at a 
rate of 6.6 per 1,000 person-years whereas patients taking rivaroxaban had an incidence 
of ischemic stroke or systemic embolism of 8.0 per 1,000 person-years (hazard ratio 0.82, 
95% Confidence interval 0.68-0.98).13 The authors also related that patients taking 
apixaban had a lower rate of gastrointestinal bleeding and hemorrhagic stroke at 12.9 per 
1,000 person-years, compared to patients taking rivaroxaban at 21.9 per 1,000 person-
years (hazard ratio 0.58, 95% Confidence interval 0.52-0.66).13 Although this study 
suggests that apixaban may be more effective and less harmful than rivaroxaban for 
reducing incidence of ischemic stroke, systemic embolism, gastrointestinal bleeding and 
hemorrhagic stroke, the authors do outline many limitations of their analysis. Because the 
study was retrospective and observational, the authors were unable to control for 
unmeasured confounding variables (such as aspirin use, renal function, and body mass 
index between the two groups). Despite these limitations, this study does echo findings 
from prior retrospective studies in which apixaban and rivaroxaban were compared. In a 
2019 retrospective population-based cohort study, over 15,000 patients either taking 
apixaban or rivaroxaban were examined for risk of recurrent thromboembolism and 
major bleeding events. Patients taking apixaban were noted to have an incidence of 
recurrent thromboembolism of 3 per 100 person-years compared to the rivaroxaban group 
who experienced an incidence of 7 per 100 person-years (hazard ratio 0.37, 95% 
Confidence interval 0.24-0.55, p < 0.0001).14 Those taking apixaban also experienced 
less major bleeding (3 per 100 person-years compared to 6 per 100 person-years in the 
rivaroxaban group [hazard ratio 0.54, 95% Confidence interval 0.37-0.82, p = 0.0031]).14 
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The findings of these two large retrospective studies suggest that apixaban may be a 
better option than rivaroxaban.  
A recent meta-analysis examined results from DOAC versus warfarin trials and 
highlighted a difference between apixaban and dabigatran. The meta-analysis found 
dabigatran was associated with a higher risk of major bleeding compared to apixaban 
(hazard ratio 1.37, 95% Confidence interval 1.14-1.67).15 While this meta-analysis does 
pull data from multiple trials that were not controlled in the same way, it does highlight a 
potential shortcoming of dabigatran when compared to apixaban. The nature of this 
relationship not being explored in a head-to-head study should be emphasized. However, 
it is unlikely that dabigatran, or any DOAC, will be directly compared to apixaban.  
Given its tendency for less major bleeding compared to rivaroxaban and 
dabigatran, lower chance of recurrent thromboembolism compared to rivaroxaban, and 
absence of need for renal function monitoring, apixaban has been chosen as the DOAC 
that will be used in our study. 
Review for Confounding Variables 
Major Studies 
 There have been three main studies examining the use of Watchman in AF 
patients. These are the PROTECT AF, PREVAIL, and EWOLUTION trials. The 
PROTECT AF and PREVAIL trials were unblinded randomized control trials in which 
Watchman therapy was compared to warfarin therapy. The EWOLULTION study was a 
multicenter, prospective, nonrandomized cohort study aimed at assessing the safety and 




In the PROTECT AF trial, the first study of the Watchman device, operators with 
more experience deploying Watchman had a lower peri-procedural complication rate of 
peri-device leakage and device embolization.16 In the subsequent PREVAIL trial, no such 
impact of the procedural learning curve was observed: implantation success was achieved 
by 96.3% of experienced operators and 93.2% of new operators (p = 0.256).17 This may 
have reflected improvement in the ability of the company proctors who attended the 
procedures becoming better teachers of new implanters. In the third Watchman study, the 
EWOLUTION trial, 75% of Watchman cases were performed by operators with less than 
2 years of Watchman experience. Periprocedural adverse events occurred at a very 
respectable low rate of 1.5% with only one case of device embolization requiring 
surgery.18 Another prospective study examined the effect of operator experience on the 
incidence of major adverse cardiac events, including mortality, stroke, bleeding, and 
vascular complications. This study showed that across three separate operator groups 
with differing levels of experience, major adverse cardiac event outcomes were similar 
(odds ratio 0.59, 95% Confidence interval 0.15-2.29, p = 0.45).19 While it is impossible to 
completely rule out operator experience as a confounding variable, the literature does 
suggest that it may not play a significant role in influencing the results of our study. 
Moreover, physicians in the Yale New Haven Health System, as of April 1, 2020, have 
performed more than 150 Watchman procedures (personal communication: Dr. Craig 
McPherson, Director, Cardiac EP Service at Bridgeport Hospital), so operator experience 
is not expected to have any significant impact on our study. 
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Review of Methodology 
 Selection of Patients 
 In the PROTECT AF trial, patients were screened for the type of AF that they had 
and their CHADS score (with the more current scale being the CHA2DS2VASc score). A 
patient with a CHADS score of one or greater would be estimated to have a greater than 
2% annual risk of stroke. Patients in the PROTECT AF trial were required to have a 
score of one or greater.16 Patients in the PREVAIL trial were required to have a score of 
two or greater.17 Patients in the EWOLUTION study did not have a required CHADS 
score.18 CHADS/ CHA2DS2VASc scores will not be used as a selection criterion for the 
present study due to the clinical benefit that has already been demonstrated by Watchman 
for AF patients. This study aims to focus on the difference in anticoagulation regimens 
for the already FDA approved Watchman. Although CHA2DS2VASc scores may be used 
to characterize patients in outcome analysis they will not be part of the inclusion criteria. 
The patients included in this study will be those who have already been selected for 
Watchman implantation by their managing physicians in consultation with the members 
of the Electrophysiology Service staff.  
Monitoring for Thrombus Formation 
 The occurrence of thrombus formation on the Watchman device is the primary 
outcome of the proposed study. The imaging modality used in the PROTECT AF, 
PREVAIL, and EWOLUTION trials was transesophageal echocardiography.16-18 A recent 
meta-analysis examined whether another modality of imaging, intracardiac 
echocardiography, was feasible and useful in this population. The authors reviewed 42 
studies and determined that transesophageal echocardiography and intracardiac 
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echocardiography gave similar results when comparing procedural success, (relative risk 
1.00, 95% Confidence interval 0.97-1.03, p = 0.98) complications, (relative risk 0.77, 
95% Confidence interval 0.52-1.15, p = 0.20) and procedural time (mean difference -
8.02, 95% Confidence interval -22.81-6.76, p = 0.29).20 Given that intracardiac 
echocardiography is an invasive study, requiring cannulation of a femoral vein, 
transesophageal is a somewhat less invasive procedure that lends itself well to performing 
post-implant follow-up in patients. It is the clinical gold standard imaging modality for 
detecting thrombus formation in the left atrium and on implanted left atrial appendage 
occlusion devices and, therefore, will be the imaging modality used in the present study. 
 It is imperative to monitor the device for thrombus formation due to the observed 
increased risk of embolic stroke. A 2018 study that analyzed the incidence of device-
related thrombus after left atrial appendage occlusion found an incidence of device-
related thrombus to be 7.2%. The study also demonstrated an increased risk of ischemic 
strokes and transient ischemic attacks in patients with a device-related thrombus (hazard 
rate 4.39, 95% Confidence interval 1.05-18.43, p = 0.04).21 Another 2018 study analyzed 
device-related thrombus after Watchman implantation and came to similar conclusions. 
The incidence of device-related thrombus was lower in this study at 3.7%, however 
patients with a device-related thrombus were more likely to develop stroke or systemic 
embolism compared to those who did not develop device-related thrombi (adjusted rate 
ratio 3.55, 95% Confidence interval 2.18-5.79, p < 0.001).22 These two studies highlight 
the importance of adequate anticoagulation after left atrial appendage occlusion and 
demonstrate the adverse events that are possible if a thrombus forms on the device.  
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 The time period of monitoring for thrombus formation is also important to 
consider. In the PROTECT AF and PREVAIL trials, transesophageal echocardiography 
was completed at 45 days, 6 months, and 12 months after implantation of the 
Watchman.16,17 A length of 45 days was deemed long enough in these trials for 
endothelialization of the device to occur. Once this has occurred, there should no longer 
be a substantial risk of forming a thrombus on the device. At 45 days, patients with no 
thrombus formation were transitioned off anticoagulant therapy and placed on dual 
antiplatelet therapy. Another transesophageal echocardiogram was performed at 6 months 
after device implantation. This was to ensure that patients were not developing thrombus 
formation while off anticoagulation therapy. The transesophageal echocardiogram 
performed 12 months post-implant was a precautionary measure to ensure that no 
thrombus formation had occurred after patients were transitioned to aspirin monotherapy. 
Neither study found a significant number of patients with device thrombus formation at 
the 12 months period.16,17 These studies support our use of transesophageal 
echocardiography for thrombus formation surveillance and our proposed timeline of post-
implant imaging, which follows current clinical practice.  
Therapy Transitioning Timing 
 The decision on when to transition therapy from systemic anticoagulantion to dual 
antiplatelet therapy to eventual antiplatelet monotherapy is also described in the 
literature. In the PROTECT AF and PREVAIL trials, warfarin therapy was administered 
during the first 45 days after implantation in order to prevent thrombus formation while 
device endothelialization occurred. Low dose aspirin was also part of the antithrombotic 
therapy during this 45-day period. As described above, if there was an absence of 
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thrombus formation and an absence of peri-device leakage by transesophageal 
echocardiography at 45 days, patients were transitioned from warfarin and aspirin to dual 
antiplatelet therapy consisting of clopidogrel and high dose aspirin. At 6 months if there 
were no complications or evidence of device thrombus formation, then patients would 
discontinue clopidogrel therapy and continue with lifelong high dose aspirin therapy.16,17 
Again, this logic is sound due to the nature of the Watchman device. Once the device has 
endothelialized, the risk of thrombus formation decreases due to the body no longer 
reacting to the device as being a foreign object. At the 6-month period if patients have 
had no thrombus formation on dual antiplatelet therapy, then it is acceptable to switch 
patients to antiplatelet monotherapy for life-long treatment. These antithrombotic 
methods were also used in a recent retrospective cohort study examining the use of 
Watchman in patients at increased risk of intracranial hemorrhage with comorbid atrial 
fibrillation and a prospective study examining the use of concomitant Watchman 
deployment immediately after epicardial ablative therapy. The patients receiving 
Watchman also followed the same antithrombotic regimen stated above.23,24 Our study 
will continue with the antithrombotic schedule described due to its proven effectiveness 
and acceptance. The goal of the present study is to determine if substitution of apixaban 
for warfarin represents an equivalent, or possibly superior, therapeutic strategy. 
Conclusion 
  A thorough review of the literature examining AF and its many treatment options 
makes a few points extremely clear. It has been proven in multiple trials, including the 
RE-LY, ENGAGE AF-TIMI48, ROCKET AF, and ARISTOTLE, that DOAC 
medications are noninferior, and in some cases superior to warfarin in preventing left 
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atrial thromboembolic events in patients with AF. Specifically, DOAC medications are 
beneficial in preventing complications of AF such as: ischemic stroke, systemic 
embolism, hemorrhagic stroke, intracranial bleeding, and mortality. In cases where 
DOAC medications are simply noninferior to warfarin, it must be remembered that 
warfarin has many drug and food interactions that can create hypo/hypercoagulable 
states. DOAC medications have far fewer such interactions and are more convenient for 
patients, which may improve compliance with therapy. 
 Among the DOAC medications, it has been noted in multiple studies that 
apixaban appears to be the medication with the least amount of adverse events while 
providing the most benefit. That is why it has been chosen for use in the present study. 
 In 2015, as a result of two randomized trials, the Watchman left atrial appendage 
occlusion device was approved by the FDA for the prevention of left atrial 
thromboembolism in patients with nonvalvular AF.  
 The current standard of care for antithrombotic therapy after Watchman 
implantation consists of warfarin and aspirin, transitioning to dual antiplatelet therapy 
with clopidogrel and aspirin, and finally to aspirin monotherapy. This antithrombotic 
regimen was empirically developed and has not been tested in a randomized control trial. 
Current literature suggests that DOAC therapy may be a better antithrombotic regimen 
than warfarin for preventing device-associated thrombus formation in the first three to six 
months after Watchman implantation. 
 The currently proposed study aims to assess whether substituting the DOAC 
apixaban for warfarin during the first 45 days post-implantation of Watchman will be 
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noninferior to the current warfarin-based standard of care. Due to the nature of apixaban 
carrying a less burdensome side effect profile, no need for routine monitoring, and fewer 
drug and food interactions, this medication could be more beneficial than warfarin for 
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 The proposed study will be a prospective, single (specific clinician) blinded, 
single health system, randomized controlled trial. The trial will take place in the Yale 
New Haven Health system at the New Haven, St. Raphael, and Bridgeport campuses. 
Study Population and Sampling 
 The population will consist of men and women with nonvalvular atrial fibrillation 
who are referred for Watchman device therapy. Individuals who meet inclusion criteria 
and do not meet exclusion criteria will be enrolled on a consecutive basis as they are 
referred and will be randomized as they are accepted to the study (inclusion and 
exclusion criteria found in Table 1). The study will aim to enroll 340 patients to the 
study, 170 in the control group and 170 in the intervention group in order to establish a 
noninferiority outcome. 
Inclusion Criteria Exclusion Criteria 
Age > 18 Reasons for long term anticoagulation other than atrial fibrillation 
Nonvalvular Atrial fibrillation Contraindication to warfarin or aspirin 
Eligible for long term warfarin therapy Prior stroke or transient ischemic attack within the last 90 days 
Eligible to come off warfarin therapy Symptomatic carotid disease 
 Atrial septal defect requiring treatment 
Table 1: Inclusion and Exclusion Criteria 
Subject Protection and Confidentiality 
 Study participation will remain confidential to all personnel not directly involved 
with the study. Participants will be monitored throughout for adverse events, including 
stroke, systemic embolism, gastrointestinal bleeding, intracranial hemorrhage, and 
mortality. If a safety threshold is met, the study will be discontinued and all remaining 
patients will be moved to the group not experiencing the adverse events. The safety 
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threshold and number/severity of adverse events required to meet the threshold will be 
established by an outside ethics board. 
Recruitment 
 The Bridgeport and New Haven campuses of the Yale New Haven Health system 
are currently eligible to proceed with the Watchman implantation procedure. These two 
campuses will be asked to refer patients that are sent for Watchman therapy to our study. 
The study will be described to the clinicians and with their permission the patients will be 
invited to participate. Patients will be informed of the benefits and risks associated with 
the study. With the patient’s consent, they will be added to our sample list and 
randomized into either the control or intervention arm of the study. Patients will be 
randomized before their procedure date. 
Study Methods 
 Participants will be instructed to discontinue oral anticoagulation 24 hours pre-
procedure. Participants will be placed under general anesthesia and the Watchman device 
will be placed in the standard manner, percutaneously via a trans-septal approach under 
transesophageal echocardiographic and fluoroscopic imaging guidance. Clinicians will be 
able to choose from devices ranging in size between 21 and 33 millimeters. The choice of 
device size will be determined, as per current standard of practice, by the clinician based 
upon pre-implant echocardiographic imaging of the left atrial appendage. 
 After the device has been implanted, patients in the intervention group will be 
anticoagulated with 5 mg apixaban twice daily and 75 mg clopidogrel while patients in 
the control group will be anticoagulated with warfarin, dosed to achieve INR between 
2.0-3.5, along with 81 mg aspirin.  
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 As per standard clinical practice, patients will undergo transesophageal 
echocardiograms 45 days and 6 months after device implantation. Evidence of device 
endothelialization, flow < 5 mm in width, and absence of device related thrombus on 
transesophageal echocardiogram at 45 days will permit transition of antithrombotic 
therapy from apixaban/warfarin to dual antiplatelet therapy. Dual antiplatelet therapy will 
consist of 75 mg clopidogrel and 324 mg aspirin daily for both the intervention group and 
control group. Participants who do not show evidence of device endothelialization or who 
show evidence of device related thrombus will be continued on their respective 
anticoagulation medication for another 7 days. After 7 days, the participant will be 
reassessed under transesophageal echocardiography. This is a decision made by the 
research team and has not been used as standard practice. This process will continue until 
the participant shows evidence of device endothelialization and there is no evidence of 
device related thrombus. 
 At 6 months post-procedure, patients will be reassessed with transesophageal 
echocardiography for presence of device related thrombus. If the participant shows 
evidence of device related thrombus, they will be restarted on their respective oral 
anticoagulation. If the patient shows no signs of device related thrombus, clopidogrel will 
be discontinued and the patient will continue with 324 mg of aspirin daily. 
Study Variables and Measures 
Dependent variable: the dependent variable measured in this study will be presence of 
device thrombus. This is due to the correlation between existence of a thrombus and 
development of ischemic stroke and systemic embolism. Thrombus formation will be 
assessed at the transesophageal echocardiograms at 45 days and 6 months. 
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Independent variable: the independent variable is the choice of anticoagulant, between 
apixaban and warfarin. 
Control variables: the control variables include: 1) the transition to dual antiplatelet 
therapy will be the same in both groups, at day 45 post-implant if there is no evidence of 
device related thrombus or peri-device leakage; 2) the agents for dual antiplatelet therapy 
will be the same as previously stated in the literature, 75 mg clopidogrel and 324 mg 
aspirin; 3) at 6 months post procedure, both groups will be transitioned from dual 
antiplatelet therapy to aspirin monotherapy at 324 mg per day. 
Methodology Considerations 
 This study relies on patients adhering to their scheduled medication regimens, 
whether that is taking the proper dose of warfarin each day or remembering to take their 
apixaban. This part of the study will not be influenced by any extra outside forces in 
order to maintain generalizability of the study. The advantages and limitations of this 
decision will be discussed in chapter 4. 
 The decision to only blind the clinician responsible for echocardiographic 
interpretation was made to increase the ease of the study. More information can be found 
under the following section. 
 The decision to monitor patients for a total of 6 months is due to this being the 
time period where they are most likely to form a thrombus and is the current standard of 
clinical practice. Any thromboembolism risk outside of this time period has been shown 




Blinding of Intervention 
This is a single blinded study in which the only individuals who need to be 
blinded are the clinicians that read the echocardiographic images, who will be blinded to 
the antithrombotic regimen that each study subject is receiving. The patients do not need 
to be blinded because their knowing which drug they are taking cannot reasonably 
influence the incidence of thrombus formation on the device. The clinicians providing 
care to the patients do not need to be blinded because their knowledge of the patient’s 
care is also not likely to affect the occurrence of device-related thrombus formation. This 
will also reduce the difficulty of the study for both patients and providing clinicians. 
Control group patients will be able to have their INR monitored regularly and their 
warfarin dose adjusted as needed. Intervention group patients will have no need to 
undergo routine blood testing and will be monitored by their clinicians according to the 
protocols for apixaban.  
Blinding of Outcome 
 As stated above, the clinicians interpreting the transesophageal echocardiographic 
images are the only individuals involved with the study subjects who will be blinded to 
the antithrombotic therapy that each subject is receiving. Patients and other providing 
clinicians are able to know the results of the transesophageal echocardiographic images 
without influencing the results of the study. 
Assignment of Intervention 
 The assignment of intervention will take place immediately following referral of 
patients to our study and before the patient undergoes Watchman implantation. A random 
number generator will be used with numbers between 1-340. Patients who receive an odd 
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number will be placed into the control group while patients who receive an even number 
will be placed in the intervention group. Once a number is selected from the random 
number generator, it will be removed from the sequence, meaning that there can be only 
one patient that is assigned to each study number. This will ensure an equal number of 
patients in each group and as we attempt to reach our target sample size of 340 patients. 
Randomization of the patients can be done by the investigators due to the fact that they 
will not be blinded to group assignment of the patients.  
Adherence 
 Adherence to anticoagulation in the first 45 days and continued dual antiplatelet 
therapy up to 6 months will not be directly monitored in this study. The control group 
will have minor indirect monitoring of their anticoagulation compliance due to the INR 
checks that are required for patients taking warfarin. There are no other parts of the study 
that require adherence monitoring due to the nature of an implantable device. The 
implications and limitations of not monitoring adherence will be discussed in chapter 4. 
Monitoring of adverse events 
 Adverse events will be monitored through routine clinician visits. Patients in the 
control group will already be attending periodic visits for INR checks. In these visits, the 
clinician will also ask if the patient has experienced any abnormal bleeding or other side 
effects. The intervention group will not be brought in for frequent clinical visits, but these 
patients will be called by a nurse on a weekly basis in order to monitor for adverse events 
including any bleeding, signs of peripheral embolization, symptoms of splenic or renal 
infarction (abdominal or flank pain, darkening of urine) or any new neurological 
symptoms. Patients will be encouraged to take all of their medications as prescribed and 
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to report any new symptoms, alterations of medications by their physicians (especially 
any interruption of their prescribed antithrombotic therapy), any visits to an urgent care 
or emergency department and any hospital admissions that they undergo during the year 
following device implantation. 
Data Collection 
 Data collection will be completed within 2 years of the study start date, including 
up to 18 months of recruitment/enrollment and 6 months of follow up. Each patient will 
begin follow-up after their procedure, meaning that statistical analysis will have to wait 
until all 340 patients have completed 6 months of follow-up. Baseline patient data will be 
gathered through medical record review and interview when the patient enrolls in the 
study. CHA₂DS₂-VASc and HAS-BLED scores will be calculated when participants are 
enrolled in the study. The event rate of device thrombus formation will be assessed at 45 
days and 6 months by transesophageal echocardiographic interpretations performed by 
blinded clinicians. 
Sample Size Calculation 
 This trial seeks to demonstrate that apixaban is noninferior to standard warfarin 
therapy post-Watchman implant. The anticipated outcome of the primary event (device-
related thrombus detected by transesophageal echocardiogram) was estimated using data 
from the PREVAIL trial, in which such thrombus occurred in 6.4% of patients. Although 
our trial is not specifically examining ischemic stroke, systemic embolism, or mortality as 
study endpoints (because their anticipated occurrence is low), these events will be 
catalogued to characterize patient outcomes. Transesophageal echocardiography is the 
imaging modality of choice when assessing for left atrium thrombus and will be used in 
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our study to track the efficacy of anticoagulation. The anticipated outcome in our 
intervention group was estimated from the results of the ARISTOTLE trial comparing 
apixaban and warfarin. In that study, patients treated with apixaban experienced 20% 
fewer episodes of stroke and systemic embolism when compared to warfarin. Using this 
information, we estimated a 20% reduction in primary event outcome for our intervention 
arm, giving a value of 0.051. The alpha was set to 0.05 and the power was set to 0.80. 
Due to this study being noninferiority in nature, the statistical difference between the 
control and treatment arms will be judged by a one tail test. Our calculation also relies on 
the event rate in the intervention arm being as low as the event rate in the control arm due 
to our outcome event being a poor outcome (instead of a positive one such as increased 
vision). The acceptable difference for this calculation was set to 0.05, reflecting the 
standard noted in previous literature. This calculation produced a sample size of 170 
individuals for each arm of the trial, bringing our sample population to 340 individuals. 
Analysis 
 Baseline participant characteristics, CHA₂DS₂-VASc scores, and HAS-BLED 
scores will be compared between intervention and control groups with ꭓ2 tests. Due to our 
study assessing a dichotomous outcome variable at specific points in time, 45 days and 6 
months, we will use simple logistic regression. This value will then be compared between 
the two groups using person-time (days).  
Timeline and Resources 
 Timeline: pending IRB approval, enrollment for the study will begin on January 
1, 2021. Enrollment will continue until June 25, 2022 to ensure that those that are 
enrolled, even up to the deadline, will have adequate time to undergo the procedure and 
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follow-up for 6 months. The primary outcome data will be collected at 45 days and 6 
months of follow-up. Data analysis will commence on January 1, 2023. 
 Personnel: Due to the single blinded nature of this study, in which clinicians 
interpreting the echocardiograms are the only ones being blinded, minimal personnel will 
be required. A study-specific assistant will be needed to coordinate patient enrollment, 
treatment randomization, and entry of information and data into the study database. 
Investigators will be unblinded, and therefore will be able to receive information on 
patient echocardiogram results. An independent team will monitor the study for number 
and severity of adverse events and be in charge of deciding whether or not the study 
needs to be discontinued early due to ethical reasons.  
 Location: This trial will take place in the Yale New Haven Health System at the 
Yale New Haven, St. Raphael, and Bridgeport Hospital campuses. The Watchman device 





 There are numerous potential advantages in the present clinical care of patients 
undergoing Watchman implant that may result from this study. Apixaban, if found to be 
at least not inferior to warfarin therapy may simplify the care of patients undergoing 
Watchman implant. Frequent blood testing to monitor INR will not be required. Potential 
interactions with other medications will be of lesser concern. Patients may realize fewer 
dietary restrictions, since alcohol and certain foods do not interact with apixaban as they 
do with warfarin. This may also result in fewer instances of device-related thrombosis or 
severe bleeding since the level of anticoagulation on apixaban may not vary erratically as 
it sometimes does in patients taking warfarin. Moreover, apixaban has demonstrated 
lower risk of intra-cranial bleeding than warfarin. Finally, apixaban may prove to be 
superior to warfarin in preventing Watchman-related thrombosis (and subsequent stroke 
from cerebral embolism) as it proved to be in the ARIATOTLE study.  The study design 
may prove to be advantageous as it allows this study to be a single blind, which 
simplifies study conduct. Finally, study design may permit its expeditious completion. 
Enrollment is simplified, the drugs employed are non-experimental, clinically available 
agents that are in wide use, the study protocol follows the protocol for Watchman implant 
and follow-up that is in present use and enrolled subjects are not asked to undergo any 
experimental or extraneous procedures. All of these features may facilitate patient 




 Our study does present some limitations in its design. Drug compliance will not 
be monitored by pill counting. This is not felt to be necessary. Warfarin therapy will be 
monitored by INR testing as per routine clinical practice. Patients will be periodically 
contacted to assess for any symptoms and remind them of the importance of medication 
compliance. It is anticipated that such procedures will be sufficient to insure medication 
compliance. Another potential limitation is that the compliance of warfarin patients 
following the restrictive diet required will not be scrupulously monitored.  Many foods 
interact with warfarin, either increasing or decreasing its anticoagulant level. This mirrors 
usual clinical practice and may make the results of the study more generalizable to usual 
clinical practice. 
Clinical and Public Health Significance 
 Our study aims to improve the management and treatment of patients with atrial 
fibrillation. As our population continues to age, atrial fibrillation will become an even 
more prevalent issue. The current Watchman antithrombotic profile has not been 
rigorously studied, leaving questions about its safety and efficacy unanswered. As left 
atrial appendage occlusion devices, such as the Watchman, become more frequently used, 
it is imperative that the literature provides clinicians with evidence based trials for which 
to use to guide antithrombotic therapy after device implantation. Our proposed study will 
assess the use of apixaban for anticoagulation after Watchman implantation compared to 
warfarin. If our study is successful, this will prevent patients from having to adhere to the 
stringent protocols surrounding warfarin therapy, such as modified diets and continuous 
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monitoring of INR. Our study will hopefully pave the way to an easier antithrombotic 














 Recruitment flyers will not be necessary for this study. Patients will be referred to 
our study by their electrophysiology physicians; none will be recruited from the general 
public or local cardiologists. The research assistant will be responsible for reviewing the 
EP Lab and OR schedules and identifying potential patients for the study. When a 
potential patient is identified, the research assistant will ask the electrophysiologist for 
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